In addition, the FGFR1‐3 inhibitor infigratinib and the FGFR4 inhibitor FGF401 were able to effectively disrupt signaling pathways that play a key role in cell proliferation, survival, metastasis, and drug resistance, thus exhibiting potent antitumor activity in tumor models of HCC with FGFR2/3 or FGF19/FGFR4 high‐expression.58 This evidence concerns the gene FGF19 and hepatocellular carcinoma.